[CG Roster]

The Cancer Genetics [CG] Study Section reviews grant applications related to the causal agents and target genes involved in tumor pathogenesis.  Organ-specific carcinogenesis is included in this study section.  Studies using both mammalian and non-mammalian models are included.

Specific areas covered by CG include:

• Oncogene discovery, genomics, and proteomics (including molecular and biochemical profiling)
  
  
• Positional cloning
  
  
• Animal models for gene discovery
  
  
• Cancer genetics: including hereditary and somatic DNA alterations, allelic imbalance/LOH
  
  
• Epigenetics: including DNA methylation and imprinting
  
  
• Metabolizing enzyme polymorphisms and mutations
  
  
• Genomic instability: including microsatellite and chromosomal instability
  
  
• Susceptibility/modifier genes that modify susceptibility to cancer without allelic loss including low penetrance genes identified in human and animal models 

CG has the following shared interests within the ONC IRG:

• With Cancer Etiology [CE] in development of early biomarkers and in organ-specific carcinogenesis.  If emphasis is in the etiology of disease, the application could be assigned to CE, in general other genetic studies could be assigned to CG.
  
  
• With Tumor Progression and Metastasis [TPM] as it relates to tumor progression.  If genetic control of tumor progression is the central focus, the application could be assigned to TPM.
  
  
• With Cancer Biomarkers [CBSS] regarding discovery and evaluation of genetic and epigenetic abnormalities in tumors that may serve as clinical biomarkers.  When the focus is on identification of biomarkers for clinical applications, the proposal could be assigned to CBSS; when the focus is on understanding the disease process, the applications could be assigned to CG.
  
  
• With Radiation Therapeutics and Biology [RTB] in genomic instability: If the instability relates to radiation effects, the application could be assigned to RTB; other examples of genomic instability could be assigned to CG.
  
  
• With Drug Discovery and Molecular Pharmacology [DMP] in studies of processes and targets involved in oncogenesis. Pharmacological studies could be assigned to DMP while studies focused on cancer genetics could be assigned to CG.

CG has the following shared interests outside the ONC IRG:

• With the Genes, Genomes and Genetics [GGG] IRG:  In general, if the findings could also be relevant to another area of biomedical research, the study could be assigned to GGG; fundamental genetic and gene function studies uniquely relevant to oncology could be assigned to CG.
  
  
• With the Hematology [HEME] IRG: In general studies of the genetics of lymphoma and leukemia could be assigned to CG. 
  
  
• With the Endocrinology, Metabolism, Nutrition and Reproductive Sciences [EMNR] IRG:  In general, studies of the genetics of endometrial hyperplasia; trophoblast neoplasia; germ cell tumors; pituitary adenomas; as well as thyroid, parathyroid, and adrenal tumors could be assigned to EMNR; studies of genetics of reproductive organ tumors could be assigned to CG.
  
  
• With the Digestive Sciences [DIG] IRG: In general, genetic studies of the pre-neoplastic stages of GI, liver, or pancreas could be assigned to DIG; genetic studies of GI, liver, or pancreatic cancers could be assigned to CG.
  
  
• With the Renal and Urological Sciences [RUS] IRG:  In general, genetic studies focused on the malignant transformation in the context of urinary tract or kidney development or other diseases; or studies focused on benign processes in the kidney, urinary tract, or male genital system could be assigned to RUS; genetic studies of malignant transformation focused on the neoplastic process could be assigned to CG.  Studies of genes and their products that are involved in both neoplastic and normal developmental processes (e.g., WT1 and VHL) could be assigned to RUS or CG, depending on the focus of the study.